Eli Lilly and Company’s (LLY) “Buy” Rating Reaffirmed at Deutsche Bank Aktiengesellschaft

Eli Lilly and Company (NYSE:LLY)‘s stock had its “buy” rating reissued by analysts at Deutsche Bank Aktiengesellschaft in a report released on Thursday, Benzinga reports. They presently have a $1,025.00 target price on the stock. Deutsche Bank Aktiengesellschaft’s price target suggests a potential upside of 15.95% from the stock’s current price.

LLY has been the topic of several other research reports. BMO Capital Markets upped their price target on shares of Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the stock an “outperform” rating in a report on Friday, August 9th. Citigroup started coverage on shares of Eli Lilly and Company in a report on Friday, September 13th. They issued a “buy” rating and a $1,060.00 price target on the stock. Jefferies Financial Group upped their price target on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a report on Monday, June 24th. JPMorgan Chase & Co. upped their price target on shares of Eli Lilly and Company from $1,050.00 to $1,100.00 and gave the stock an “overweight” rating in a report on Friday, September 13th. Finally, Truist Financial reaffirmed a “buy” rating and issued a $1,000.00 price target (up previously from $892.00) on shares of Eli Lilly and Company in a report on Tuesday, June 25th. Three equities research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $977.35.

Eli Lilly and Company Stock Performance

LLY stock traded down $7.07 during midday trading on Thursday, reaching $884.00. 1,146,221 shares of the company’s stock traded hands, compared to its average volume of 3,032,312. The company has a 50-day moving average price of $897.24 and a two-hundred day moving average price of $846.22. The company has a debt-to-equity ratio of 1.74, a quick ratio of 0.87 and a current ratio of 1.11. Eli Lilly and Company has a 52 week low of $523.63 and a 52 week high of $972.53. The firm has a market capitalization of $840.16 billion, a PE ratio of 130.28, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a net margin of 18.86% and a return on equity of 67.52%. The business had revenue of $11.30 billion for the quarter, compared to analysts’ expectations of $9.83 billion. As a group, equities analysts anticipate that Eli Lilly and Company will post 16.49 EPS for the current year.

Insider Activity

In related news, major shareholder Lilly Endowment Inc sold 93,593 shares of Eli Lilly and Company stock in a transaction on Monday, July 8th. The shares were sold at an average price of $918.64, for a total value of $85,978,273.52. Following the sale, the insider now owns 97,153,810 shares in the company, valued at $89,249,376,018.40. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Over the last ninety days, insiders sold 355,962 shares of company stock valued at $331,267,535. Insiders own 0.13% of the company’s stock.

Hedge Funds Weigh In On Eli Lilly and Company

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Swedbank AB purchased a new position in shares of Eli Lilly and Company in the first quarter worth $932,797,000. Vanguard Group Inc. lifted its position in shares of Eli Lilly and Company by 1.6% during the 1st quarter. Vanguard Group Inc. now owns 72,745,011 shares of the company’s stock valued at $56,592,709,000 after buying an additional 1,133,810 shares in the last quarter. Wulff Hansen & CO. boosted its position in shares of Eli Lilly and Company by 90,438.0% in the second quarter. Wulff Hansen & CO. now owns 937,068 shares of the company’s stock worth $848,403,000 after purchasing an additional 936,033 shares during the period. GQG Partners LLC boosted its holdings in Eli Lilly and Company by 20.2% in the 1st quarter. GQG Partners LLC now owns 3,848,886 shares of the company’s stock worth $2,994,280,000 after buying an additional 648,094 shares during the period. Finally, Comerica Bank grew its position in shares of Eli Lilly and Company by 71.6% during the second quarter. Comerica Bank now owns 1,512,983 shares of the company’s stock worth $1,369,825,000 after purchasing an additional 631,312 shares in the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.